Edition:
United Kingdom

Granules India Ltd (GRAN.NS)

GRAN.NS on National Stock Exchange of India

97.05INR
26 Jun 2019
Change (% chg)

-- (--)
Prev Close
Rs97.05
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
950,332
52-wk High
Rs123.40
52-wk Low
Rs76.45

Latest Key Developments (Source: Significant Developments)

Granules India March-Qtr Consol Profit Rises
Thursday, 9 May 2019 

May 9 (Reuters) - Granules India Ltd ::MARCH QUARTER CONSOL PROFIT 640.4 MILLION RUPEES VERSUS 204.4 MILLION RUPEES YEAR AGO.MARCH QUARTER CONSOL REVENUE FROM OPERATIONS 6.13 BILLION RUPEES VERSUS 5.04 BILLION RUPEES YEAR AGO.RECOMMENDED DIVIDEND OF 0.25 RUPEES PER SHARE.APPROVED THE RE-APPOINTMENT OF KRISHNA PRASAD CHIGURUPATI AS MANAGING DIRECTOR.APPROVES RESIGNATION OF K. GANESH AS CHIEF FINANCIAL OFFICER.  Full Article

India's Granules India Dec Quarter Consol Profit Surges
Tuesday, 29 Jan 2019 

Jan 29 (Reuters) - Granules India Ltd ::DEC QUARTER CONSOL PROFIT 603.2 MILLION RUPEES VERSUS PROFIT 350.2 MILLION RUPEES YEAR AGO.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 6.32 BILLION RUPEES VERSUS 4.11 BILLION RUPEES YEAR AGO.DECLARED INTERIM DIVIDEND OF 25 PAISE PER SHARE.  Full Article

Granules India Says Gets Approval For ANDA Filed By Granules Pharmaceuticals
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Granules India Ltd ::SAYS RECEIVED APPROVAL FOR ANDA FILED BY GRANULES PHARMACEUTICALS, INC.SAYS GRANULES PHARMACEUTICALS, INC. SHALL MARKET AND DISTRIBUTE THE PRODUCT SHORTLY..  Full Article

Granules India Says U.S. FDA Approves ANDA For Metformin Extended Release Tablets
Monday, 19 Mar 2018 

March 19 (Reuters) - Granules India Ltd ::USFDA APPROVED ANDA FILED BY CO FOR METFORMIN EXTENDED RELEASE (ER) TABLETS 500 MG AND 750 MG.SAYS CO INTENDS TO COMMERCIALISE PRODUCT SHORTLY.  Full Article

Granules India Says U.S. FDA Issued EIR For Unit's Facility In Virginia
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Granules India Ltd ::SAYS U.S. FDA ISSUED EIR FOR GRANULES PHARMA FACILITY IN CHANTILLY, VIRGINIA.SAYS FACILITY INSPECTED BY U.S. FDA IN DEC; THERE WAS ONE OBSERVATION.SAYS RESPONDED TO OBSERVATION WITHIN STIPULATED TIMEFRAME.  Full Article

Granules India Dec Qtr Consol Profit Falls
Thursday, 8 Feb 2018 

Feb 8 (Reuters) - Granules India Ltd ::DEC QUARTER CONSOL NET PROFIT 350.2 MILLION RUPEES VERSUS 390.6 MILLION RUPEES YEAR AGO.DEC QUARTER CONSOL REVENUE FROM OPERATIONS 4.11 BILLION RUPEES VERSUS 3.59 BILLION RUPEES YEAR AGO.DECLARED INTERIM DIVIDEND OF 0.25 RUPEES PER SHARE.  Full Article

Granules India's Virginia Unit Completes U.S. FDA Audit With 1 Observation
Monday, 11 Dec 2017 

Dec 11 (Reuters) - Granules India Ltd ::SAYS GRANULES PHARMACEUTICALS COMPLETES U.S. FDA INSPECTION WITH 1 OBSERVATION.  Full Article

Granules India Sept-qtr consol profit falls
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Granules India Ltd :Sept quarter consol net profit 403.4 million rupees versus profit 408.2 million rupees year ago.Sept quarter consol revenue from operations 3.93 billion rupees versus 3.64 billion rupees year ago.Declared dividend of 0.25 rupees per share.  Full Article

Granules India says co's Omnichem facility gets EIR from U.S. FDA​
Friday, 6 Oct 2017 

Oct 6 (Reuters) - Granules India Ltd ::Co's Omnichem facility gets ‍establishment Inspection Report (EIR) from US FDA​.  Full Article

Granules India says no observations in U.S. FDA inspection at Gagillapur facility in Hyderabad
Wednesday, 16 Aug 2017 

Aug 16 (Reuters) - Granules India Ltd :Says US FDA issued EIR for Gagillapur facility at Hyderabad.Facility inspected by US FDA in oct 2016 and there were no observations during inspection at Gagillapur facility in Hyderabad, Telangana.  Full Article